Telemedicine or Standard Care in Treating Patients With Depression and/or Pain Caused By Cancer
19 de septiembre de 2013 actualizado por: Indiana University Melvin and Bren Simon Cancer Center
TeleCare Management of Pain and Depression in Cancer
RATIONALE: Telemedicine may help in the treatment of depression and/or pain caused by cancer. It is not yet known whether telemedicine is more effective than standard care in treating depression and/or pain caused by cancer.
PURPOSE: This phase III randomized clinical trial is studying telemedicine to see how well it works compared to standard care in treating patients with depression and/or pain caused by cancer.
Descripción general del estudio
Estado
Desconocido
Descripción detallada
OBJECTIVES:
Primary
- Compare the effectiveness of a state-wide, telemedicine intervention with standard care in cancer patients with clinical depression and/or cancer-related pain.
- Compare improvement in clinical depression and/or cancer-related pain in patients undergoing these interventions.
Secondary
- Compare health-related quality of life, functional status, and patient satisfaction with treatment in patients undergoing these interventions.
- Compare the economic benefits of these interventions in these patients.
OUTLINE: This is a randomized, longitudinal, multicenter study. Patients are stratified according to study site and type of symptom (pain only vs depression only vs pain and depression). Patients are randomized to 1 of 2 treatment arms.
- Arm I (standard care): Patients receive treatment for pain, depression, and other symptoms from their oncologist.
- Arm II (telemedicine intervention): Patients undergo automated, home-based symptom monitoring either by telephone or the Internet, depending on preference, coupled with telephonic care management by a clinical specialist. Patients complete questionnaires via the Internet or undergo standardized interviews via telephone measuring depression, pain, quality of life, and other patient-reported variables twice weekly for approximately 1 month, once weekly for 2 months, twice a month for 3 months, and then once a month for 6 months. A clinical specialist trained in treating the symptoms of pain and depression also contacts the patient by phone to assess symptom severity and initiate treatment. A follow-up call is made at 1-2 weeks to assess symptom severity, adherence, and adverse effects. Patients with depression receive 2 additional follow-up calls in the first 12 weeks. The clinical specialist also calls the patient when automated monitoring indicates inadequate symptom improvement or side effects, or the patient requests to be contacted. The clinical specialist works with the patient's regular doctor in adjusting medicines and treatment for symptoms as needed. Patients who do not complete their scheduled assessments receive an automated call or e-mail message reminding them to complete the symptoms questionnaires. Patients who do not respond to this reminder within 24 hours are contacted by the clinical specialist.
In both arms, patients are interviewed at baseline, 1, 3, 6, and 12 months. Patients are asked questions about pain, depression, other physical and emotional symptoms, work activities, quality of life, and satisfaction with treatment.
PROJECTED ACCRUAL: A total of 480 patients will be accrued for this study.
Tipo de estudio
Intervencionista
Inscripción (Anticipado)
480
Fase
- Fase 3
Contactos y Ubicaciones
Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.
Ubicaciones de estudio
-
-
Indiana
-
Anderson, Indiana, Estados Unidos, 46011
- Community Cancer Center at Community Hospital of Anderson
-
Bedford, Indiana, Estados Unidos, 47421
- Community Cancer Care at Bedford Oncology Specialty Clinic
-
Columbus, Indiana, Estados Unidos, 47201
- Columbus Regional Hospital Cancer Center
-
Greencastle, Indiana, Estados Unidos, 46135
- Community Cancer Care at Putnam County Hospital
-
Greensburg, Indiana, Estados Unidos, 47240
- Community Cancer Care at Decatur County Hospital
-
Indianapolis, Indiana, Estados Unidos, 46202
- William N. Wishard Memorial Hospital
-
Indianapolis, Indiana, Estados Unidos, 46206-1367
- Methodist Cancer Center at Methodist Hospital
-
Indianapolis, Indiana, Estados Unidos, 46219
- Community Regional Cancer Care at Community Hospital East
-
Indianapolis, Indiana, Estados Unidos, 46256
- Community Regional Cancer Care at Community Hospital North
-
Indianapolis, Indiana, Estados Unidos, 46202
- Veterans Affairs Medical Center - Indianapolis
-
Indianapolis, Indiana, Estados Unidos, 46202-2872
- Regenstrief Institute, Incorporated
-
Indianapolis, Indiana, Estados Unidos, 46202
- Community Cancer Care
-
Kokomo, Indiana, Estados Unidos, 46902
- Community Cancer Care at Howard Regional Health System
-
Madison, Indiana, Estados Unidos, 47250
- Community Cancer Care at King's Daughters' Hospital
-
Seymour, Indiana, Estados Unidos, 47274
- Schneck Medical Center
-
Tell City, Indiana, Estados Unidos, 47586
- Community Cancer Care at Perry County Hospital
-
Tipton, Indiana, Estados Unidos, 46072
- Community Cancer Care at Tipton County Memorial Hospital
-
-
Criterios de participación
Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.
Criterio de elegibilidad
Edades elegibles para estudiar
18 años y mayores (Adulto, Adulto Mayor)
Acepta Voluntarios Saludables
No
Géneros elegibles para el estudio
Todos
Descripción
DISEASE CHARACTERISTICS:
Diagnosis of cancer AND 1 or both of the following:
Clinical depression
Depression must be of at least moderate severity (PHQ-9 score ≥ 10)
- Depressed mood and/or anhedonia endorsed
- No depression directly precipitated by cancer therapy for which depression is a well known side effect (e.g., interferon, corticosteroids)
Cancer-related pain
- Pain must be at least moderate in severity (Brief Pain Inventory score ≥ 6), persisted despite using ≥ 2 analgesics, and cancer-related
- If the only pain is due to a pre-existing condition (e.g., migraine, headache, arthritis, etc), the patient may not be eligible
PATIENT CHARACTERISTICS:
- Life expectancy ≥ 6 months
- Must speak English
- Not pregnant
- Fertile patients must use effective contraception
- No moderately severe cognitive impairment
- No schizophrenia or other psychosis
- No disability claim currently being adjudicated for pain
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- Not in hospice care
Plan de estudios
Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.
¿Cómo está diseñado el estudio?
Detalles de diseño
- Asignación: Aleatorizado
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
|---|
|
Compare efficacy of 3-component model telemedicine intervention to standard care in terms of depression and pain at baseline and 1, 3, 6, and 12 months
|
Medidas de resultado secundarias
Medida de resultado |
|---|
|
Health-related quality of life at baseline and 1, 3, 6, and 12 months
|
|
Cost-effectiveness of care at baseline and 1, 3, 6, and 12 months
|
|
Treatment satisfaction at baseline and 1, 3, 6, and 12 months
|
Colaboradores e Investigadores
Aquí es donde encontrará personas y organizaciones involucradas en este estudio.
Colaboradores
Investigadores
- Silla de estudio: Kurt Kroenke, MD, Regenstrief Institute, Incorporated
Publicaciones y enlaces útiles
La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.
Publicaciones Generales
- Dube P, Kurt K, Bair MJ, Theobald D, Williams LS. The p4 screener: evaluation of a brief measure for assessing potential suicide risk in 2 randomized effectiveness trials of primary care and oncology patients. Prim Care Companion J Clin Psychiatry. 2010;12(6):PCC.10m00978. doi: 10.4088/PCC.10m00978blu.
- Kroenke K, Wu J, Yu Z, Bair MJ, Kean J, Stump T, Monahan PO. Patient Health Questionnaire Anxiety and Depression Scale: Initial Validation in Three Clinical Trials. Psychosom Med. 2016 Jul-Aug;78(6):716-27. doi: 10.1097/PSY.0000000000000322.
- Brown LF, Kroenke K, Theobald DE, Wu J, Tu W. The association of depression and anxiety with health-related quality of life in cancer patients with depression and/or pain. Psychooncology. 2010 Jul;19(7):734-41. doi: 10.1002/pon.1627.
- Kroenke K, Theobald D, Wu J, Norton K, Morrison G, Carpenter J, Tu W. Effect of telecare management on pain and depression in patients with cancer: a randomized trial. JAMA. 2010 Jul 14;304(2):163-71. doi: 10.1001/jama.2010.944.
- Kroenke K, Zhong X, Theobald D, Wu J, Tu W, Carpenter JS. Somatic symptoms in patients with cancer experiencing pain or depression: prevalence, disability, and health care use. Arch Intern Med. 2010 Oct 11;170(18):1686-94. doi: 10.1001/archinternmed.2010.337.
- Cohee AA, Kroenke K, Vachon E, Wu J, Tu W, Johns SA. Predictors of depression outcomes in adults with cancer: A 12 month longitudinal study. J Psychosom Res. 2020 Sep;136:110169. doi: 10.1016/j.jpsychores.2020.110169. Epub 2020 Jun 11.
- Choi Yoo SJ, Nyman JA, Cheville AL, Kroenke K. Cost effectiveness of telecare management for pain and depression in patients with cancer: results from a randomized trial. Gen Hosp Psychiatry. 2014 Nov-Dec;36(6):599-606. doi: 10.1016/j.genhosppsych.2014.07.004. Epub 2014 Jul 19.
- Hayano J, Carney RM, Watanabe E, Kawai K, Kodama I, Stein PK, Watkins LL, Freedland KE, Blumenthal JA. Interactive associations of depression and sleep apnea with adverse clinical outcomes after acute myocardial infarction. Psychosom Med. 2012 Oct;74(8):832-9. doi: 10.1097/PSY.0b013e31826d2c81. Epub 2012 Sep 28.
- Wang HL, Kroenke K, Wu J, Tu W, Theobald D, Rawl SM. Predictors of cancer-related pain improvement over time. Psychosom Med. 2012 Jul-Aug;74(6):642-7. doi: 10.1097/PSY.0b013e3182590904. Epub 2012 Jun 28.
Fechas de registro del estudio
Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.
Fechas importantes del estudio
Inicio del estudio
1 de febrero de 2006
Finalización primaria (Anticipado)
1 de enero de 2010
Fechas de registro del estudio
Enviado por primera vez
11 de abril de 2006
Primero enviado que cumplió con los criterios de control de calidad
11 de abril de 2006
Publicado por primera vez (Estimar)
12 de abril de 2006
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
20 de septiembre de 2013
Última actualización enviada que cumplió con los criterios de control de calidad
19 de septiembre de 2013
Última verificación
1 de mayo de 2009
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- CDR0000466348
- IUMC-051009
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .